Engineering and delivery of therapeutic compositions of freshly isolated cells

Inventors

Li, Linhong • Peshwa, Madhusudan V.

Assignees

Maxcyte Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9132153-B2

Patent

Publication Date

2015-09-15

Expiration Date


Abstract

The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.

Core Innovation

The invention provides a cell-therapy platform for transient engineering of freshly isolated, unstimulated immune cells comprising PBMCs, including peripheral blood lymphocytes, especially T cells and Natural Killer (NK) cells. Resting peripheral blood mononuclear cells are isolated and electroloaded with mRNA encoding a protein, whereby the electroloaded PBMC transiently expresses the protein.

A core technical aspect is maintaining clinically relevant viability after electroloading. The electroloaded PBMCs transiently express the protein and the viability of the electroloaded PBMCs 1 day after electroloading is at least 80% when normalized to un-electroporated PBMCs.

The described proteins include chimeric receptors, including CARs such as anti-CD19 chimeric receptors, for example anti-CD19-BBz. The platform emphasizes avoiding viral vectors and includes documented support showing chimeric receptor expression and antigen-specific target-cell killing in vitro and in vivo models.

Claims Coverage

The partial content provides two independent claims. Both independent claims focus on transient modification of unstimulated resting PBMCs by electroloading or electroporating mRNA to transiently express an encoded protein while meeting a viability constraint of at least 80% at 1 day after electroloading or electroporation when normalized to un-electroporated PBMCs.

Transiently modifying resting PBMCs by mRNA electroloading with viability threshold

A method for transiently modifying unstimulated resting peripheral blood mononuclear cells (PBMCs) by isolating resting PBMCs and electroloading the PBMC with an mRNA encoding the protein, whereby the electroloaded PBMC transiently expresses the protein and the viability of the electroloaded PBMCs 1 day after electroloading is at least 80% when normalized to un-electroporated PBMCs.

Preparing transiently modified resting PBMCs using therapeutic protein mRNA with viability threshold

A method for preparing transiently modified unstimulated resting peripheral blood mononuclear cells (PBMCs) comprising isolating resting PBMCs and electroporating the PBMC with an mRNA encoding a therapeutic protein, whereby the electroporated PBMC transiently expresses the therapeutic protein and the viability of the electroporated PBMCs 1 day after electroporation is at least 80% when normalized to un-electroporated PBMCs.

Across the independent claims, the main inventive coverage is limited to isolating unstimulated resting PBMCs and electroporating them with mRNA encoding a protein or therapeutic protein for transient expression while meeting a 1-day post-electroporation viability requirement of at least 80% relative to un-electroporated PBMCs.

Stated Advantages

Transient expression of an encoded protein in electroloaded unstimulated resting PBMCs.

Maintained viability of electroloaded PBMCs at least 80% at 1 day after electroloading when normalized to un-electroporated PBMCs.

Improved antigen-specific target-cell killing associated with expressed chimeric receptor/CAR.

Avoidance of viral vectors.

Documented Applications

Cell therapy treatment contexts involving allogeneic and autologous treatment for hyperproliferative diseases/cancer.

Expression and antigen-specific killing of leukemia or target cells using CARs, including anti-CD19-BBz, against OP-1, B-CLL target cells, and HS-Sultan leukemia cell line in vitro and in vivo models.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.